Dianthus Therapeutics (DNTH) Competitors $22.70 +1.74 (+8.30%) Closing price 04:00 PM EasternExtended Trading$22.72 +0.02 (+0.09%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. OGN, KNSA, IBRX, CNTA, ARWR, BLTE, RXRX, BHC, OCUL, and AGIOShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Organon & Co. Kiniksa Pharmaceuticals International ImmunityBio Centessa Pharmaceuticals Arrowhead Pharmaceuticals Belite Bio Recursion Pharmaceuticals Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Dianthus Therapeutics (NASDAQ:DNTH) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Do insiders and institutionals hold more shares of DNTH or OGN? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 1.4% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, DNTH or OGN? Organon & Co. has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M117.10-$84.97M-$3.25-6.98Organon & Co.$6.40B0.37$864M$2.693.43 Do analysts rate DNTH or OGN? Dianthus Therapeutics currently has a consensus price target of $53.00, suggesting a potential upside of 133.48%. Organon & Co. has a consensus price target of $18.00, suggesting a potential upside of 94.91%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Dianthus Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is DNTH or OGN more profitable? Organon & Co. has a net margin of 11.15% compared to Dianthus Therapeutics' net margin of -2,364.56%. Organon & Co.'s return on equity of 163.88% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-2,364.56% -34.72% -32.72% Organon & Co. 11.15%163.88%6.99% Does the media favor DNTH or OGN? In the previous week, Dianthus Therapeutics had 7 more articles in the media than Organon & Co.. MarketBeat recorded 15 mentions for Dianthus Therapeutics and 8 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.36 beat Dianthus Therapeutics' score of -0.06 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, DNTH or OGN? Dianthus Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. SummaryOrganon & Co. beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$674.67M$3.11B$5.73B$9.80BDividend YieldN/A2.22%4.54%4.08%P/E Ratio-6.9820.3530.7425.12Price / Sales117.10319.45441.05108.85Price / CashN/A42.8237.3459.16Price / Book2.417.698.886.24Net Income-$84.97M-$54.72M$3.26B$265.56M7 Day Performance14.07%2.03%1.73%0.90%1 Month Performance11.27%4.10%3.54%1.88%1 Year Performance-20.80%8.23%28.63%20.09% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.3542 of 5 stars$22.70+8.3%$53.00+133.5%-27.1%$674.67M$6.24M-6.9880OGNOrganon & Co.4.705 of 5 stars$9.00-2.4%$18.00+100.0%-54.4%$2.40B$6.40B3.354,000Positive NewsKNSAKiniksa Pharmaceuticals International2.5628 of 5 stars$32.74+1.8%$41.17+25.7%+29.7%$2.38B$423.24M818.70220IBRXImmunityBio2.265 of 5 stars$2.47+1.2%$12.25+396.0%-39.4%$2.31B$14.74M-5.15590CNTACentessa Pharmaceuticals2.1516 of 5 stars$16.61-2.4%$28.10+69.2%+40.7%$2.27B$6.85M-9.18200Earnings ReportAnalyst DowngradeAnalyst RevisionARWRArrowhead Pharmaceuticals3.8123 of 5 stars$17.21+4.8%$43.14+150.7%-12.3%$2.27B$3.55M-13.45400Analyst RevisionBLTEBelite Bio2.5384 of 5 stars$69.50-0.5%$96.67+39.1%+30.0%$2.22BN/A-51.1010RXRXRecursion Pharmaceuticals2.1619 of 5 stars$5.29-1.3%$7.00+32.3%-18.1%$2.18B$58.84M-2.97400Positive NewsInsider TradeBHCBausch Health Cos4.1107 of 5 stars$6.68+16.1%$9.00+34.8%+40.0%$2.13B$9.63B25.6820,700High Trading VolumeOCULOcular Therapeutix4.0355 of 5 stars$12.56+2.9%$17.20+36.9%+51.8%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.1865 of 5 stars$35.10-1.8%$56.33+60.5%-16.8%$2.08B$36.50M3.19390 Related Companies and Tools Related Companies Organon & Co. Alternatives Kiniksa Pharmaceuticals International Alternatives ImmunityBio Alternatives Centessa Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Belite Bio Alternatives Recursion Pharmaceuticals Alternatives Bausch Health Cos Alternatives Ocular Therapeutix Alternatives Agios Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access